drugset / Trial / NCT02766140
SHR1020 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Squamous Non Small Cell Lung Cancer
Phase 3
Terminated
12 enrolled
Jiangsu HengRui Medicine Co., Ltd.
Shanghai Pulmonary Hospital, Shanghai, China · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The present trial will be performed to evaluate whether SHR1020 in combination with docetaxel in patients with Local Advanced or Metastatic or recurrent Non Squamous NSCLC is more effective as compared to placebo in combination with docetaxel. A secondary aim is to obtain safety information as well as information on quality of life of patients treated with SHR1020 in combination with docetaxel.
Timeline
- Start
- 2016-06
- Primary completion
- 2016-11
- Completion
- 2016-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Famitinib | Small molecule | 20 mg | Oral |
| Background | Docetaxel | Small molecule | 60 mg/m2 | Intravenous |